Zhejiang Shengda Pharm (603079) - Total Liabilities
Based on the latest financial reports, Zhejiang Shengda Pharm (603079) has total liabilities worth CN¥561.97 Million CNY (≈ $82.23 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zhejiang Shengda Pharm - Total Liabilities Trend (2012–2025)
This chart illustrates how Zhejiang Shengda Pharm's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Zhejiang Shengda Pharm to evaluate short-term liquidity relative to the company's equity base.
Zhejiang Shengda Pharm Competitors by Total Liabilities
The table below lists competitors of Zhejiang Shengda Pharm ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kung Long Batteries Industrial Co Ltd
TW:1537
|
Taiwan | NT$1.53 Billion |
|
Lihe Technology
SHE:300800
|
China | CN¥449.77 Million |
|
Jiin Yeeh Ding Enterprise Co Ltd
TWO:8390
|
Taiwan | NT$746.42 Million |
|
Morguard Real Estate Investment Trust
TO:MRT-UN
|
Canada | CA$1.30 Billion |
|
Sungwoo Hitech Co. Ltd
KQ:015750
|
Korea | ₩3.01 Trillion |
|
Silence Therapeutics PLC
NASDAQ:SLN
|
USA | $72.73 Million |
|
Bell Financial Group Ltd
AU:BFG
|
Australia | AU$866.82 Million |
|
Antibiotice Ia
RO:ATB
|
Romania | RON548.43 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Zhejiang Shengda Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Zhejiang Shengda Pharm (603079) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Shengda Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Shengda Pharm (2012–2025)
The table below shows the annual total liabilities of Zhejiang Shengda Pharm from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥583.75 Million ≈ $85.42 Million |
+16.44% |
| 2024-12-31 | CN¥501.34 Million ≈ $73.36 Million |
+11.61% |
| 2023-12-31 | CN¥449.20 Million ≈ $65.73 Million |
+44.08% |
| 2022-12-31 | CN¥311.76 Million ≈ $45.62 Million |
-27.13% |
| 2021-12-31 | CN¥427.84 Million ≈ $62.61 Million |
+13.85% |
| 2020-12-31 | CN¥375.80 Million ≈ $54.99 Million |
-39.47% |
| 2019-12-31 | CN¥620.88 Million ≈ $90.85 Million |
+46.33% |
| 2018-12-31 | CN¥424.29 Million ≈ $62.09 Million |
+95.28% |
| 2017-12-31 | CN¥217.27 Million ≈ $31.79 Million |
-27.90% |
| 2016-12-31 | CN¥301.35 Million ≈ $44.10 Million |
+62.85% |
| 2015-12-31 | CN¥185.05 Million ≈ $27.08 Million |
-17.17% |
| 2014-12-31 | CN¥223.40 Million ≈ $32.69 Million |
-0.27% |
| 2013-12-31 | CN¥224.00 Million ≈ $32.78 Million |
-30.31% |
| 2012-12-31 | CN¥321.43 Million ≈ $47.04 Million |
-- |
About Zhejiang Shengda Pharm
Zhejiang Shengda Bio-Pharm Co., Ltd. develops, produces, and sells food and feed additives for pharmaceutical, nutritional, food, and animal feed industry. It offers vitamins, such as biotin and folic acid; biological preservatives, including nisin, polylysine, and natamycin; and intermediate APIs. The company was incorporated in 1999 and is headquartered in Tiantai, China.